Geron (NASDAQ:GERN) Sets New 52-Week Low – Should You Sell?

Geron Co. (NASDAQ:GERN)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.28 and last traded at $1.41, with a volume of 13683362 shares traded. The stock had previously closed at $1.38.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright reissued a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. Barclays restated an “overweight” rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. Stifel Nicolaus lowered their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Finally, B. Riley cut Geron from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and an average target price of $5.75.

Geron Stock Up 1.1 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business has a fifty day simple moving average of $2.11 and a 200 day simple moving average of $3.24. The firm has a market cap of $907.59 million, a price-to-earnings ratio of -4.45 and a beta of 0.66.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million. As a group, equities analysts forecast that Geron Co. will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Geron by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock worth $118,727,000 after buying an additional 1,088,912 shares during the last quarter. State Street Corp increased its position in shares of Geron by 28.4% during the 3rd quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock worth $131,486,000 after purchasing an additional 6,413,204 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Geron by 20.0% in the 4th quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock valued at $95,769,000 after buying an additional 4,516,615 shares during the period. Wellington Management Group LLP lifted its position in Geron by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company’s stock valued at $47,826,000 after buying an additional 847,710 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Geron by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 13,141,514 shares of the biopharmaceutical company’s stock worth $46,531,000 after buying an additional 73,515 shares during the period. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.